ApprovedFDA approval

Atebrioz (zilurgisertib)

Mirum Pharmaceuticals (MIRM)

Marketer take

Enters fibrodysplasia ossificans progressiva alongside Sohonos and Regeneron's Pasatru (approved five weeks earlier), so a tiny specialist community will see three-way differentiation messaging, starting with Atebrioz's label down to age 12.

Sponsor company
Mirum Pharmaceuticals (MIRM)
Indication
To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva
Therapeutic area
Rare disease
Event
FDA approval
Date
Sep 25, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move